Prices re-read October 15, 2026Methodology v4.1How we score →
Compare Providers
Home / GLP-1 / Ozempic
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Released: ·Last reviewed: ·Methodology v4.1

Researched By
Medical Researcher · Western University of Health Sciences
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.

Ozempic: what it is, cost and alternatives

Quick answer

Ozempic is the brand name for semaglutide — a glp-1 receptor agonist — FDA-approved for type 2 diabetes. Typical cost: $349/month self-pay via NovoCare ($199 for the first two fills, new patients); $499 at the 2 mg dose. List price about $1,028. As low as $25/month with commercial coverage.. Because it shares an active ingredient with other brands and with compounded preparations, patients often compare pathways on price and access.

What is Ozempic, and who is it for?

Semaglutide is a GLP-1 receptor agonist that lowers blood sugar and reduces appetite by mimicking the incretin hormone GLP-1. It is FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. In trials, weight-management dosing produced roughly 15% average body-weight reduction over 68 weeks.

For the molecule-level detail — mechanism, trial evidence, side effects and warnings — see our full semaglutide guide.

What does Ozempic cost?

$349/month self-pay via NovoCare ($199 for the first two fills, new patients); $499 at the 2 mg dose. List price about $1,028. As low as $25/month with commercial coverage.

Brand Wegovy — NovoCare self-pay price, re-read October 15, 2026
Product / doseSelf-pay priceNotes
Wegovy pill 1.5 mg$149/moSelf-pay
Wegovy pill 4 mg$199/moWas $149 through August 31, 2026 under NovoCare’s earlier price guide
Wegovy pill 9 mg and 25 mg$299/moMaintenance doses
Wegovy pen 0.25 / 0.5 mg (first 2 fills, new patients)$199/moOffer through Dec 31, 2026
Wegovy pen 0.25–2.4 mg$349/moStandard self-pay
Wegovy HD 7.2 mg$399/moSelf-pay

Our GLP-1 cost guide normalizes every cash and insured pathway side by side.

What are the alternatives to Ozempic?

Depending on eligibility and budget, patients weigh other brand GLP-1 drugs, compounded preparations where lawfully available, and lifestyle-plus-clinical programs. Compare options in our best GLP-1 programs ranking and most affordable compounded tirzepatide guide.

Frequently asked questions

What is Ozempic used for?

Ozempic is FDA-approved for type 2 diabetes. Its active ingredient is semaglutide.

How much does Ozempic cost?

$349/month self-pay via NovoCare ($199 for the first two fills, new patients); $499 at the 2 mg dose. List price about $1,028. As low as $25/month with commercial coverage.. See our cost comparison for cash and insurance pathways.

What is the difference between Ozempic and compounded semaglutide?

Ozempic is an FDA-approved finished drug. Compounded semaglutide is prepared by a pharmacy, is not FDA-approved, and its routine compounding is now restricted. See our compounded semaglutide guide.

Sources

  1. U.S. Food and Drug Administration — Ozempic prescribing information and label.
  2. Manufacturer pricing and savings program pages (verify current terms).
  3. Our normalized cost analysis, prices verified August 4, 2026.

Spotted an error? Submit a correction.

How the dates on this page work. Manufacturer self-pay prices were re-read on 15 October 2026: NovoCare’s Wegovy page and Lilly’s Zepbound savings page. Foundayo prices are carried from LillyDirect pages archived 25 September 2026, because lilly.com blocked automated reads. Figures captured from telehealth provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row or a dated notice says so. We do not restamp a figure we have not re-read.